• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Board Observer Chesed Abraham bought $65,716 worth of shares (14,286 units at $4.60) (SEC Form 4)

    10/29/25 8:43:04 PM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TTRX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Chesed Abraham

    (Last) (First) (Middle)
    25200 PRADO DEL GRANDIOSO

    (Street)
    CALABASAS CA 91302

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Turn Therapeutics Inc. [ TTRX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    Officer (give title below) X Other (specify below)
    Board Observer
    3. Date of Earliest Transaction (Month/Day/Year)
    10/23/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 10/23/2025 P 14,286 A $4.6 1,447,268 I By ANC Merchant FLP and ANC Carlson FLP(1)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Shares are held indirectly through ANC Merchant FLP and ANC Carlson FLP, each owned 48% by the reporting person, 48% by the reporting person's spouse, and 2% by each of the reporting person's two children; the reporting person disclaims beneficial ownership of the shares attributable to his spouse except to the extent of his pecuniary interest therein.
    /s/ Abraham Chesed 10/29/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TTRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TTRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TTRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Board Observer Chesed Abraham bought $65,716 worth of shares (14,286 units at $4.60) (SEC Form 4)

    4 - Turn Therapeutics Inc. (0002023016) (Issuer)

    10/29/25 8:43:04 PM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Chaudhary Zuraiz bought $24,998 worth of shares (5,050 units at $4.95) (SEC Form 4)

    4 - Turn Therapeutics Inc. (0002023016) (Issuer)

    10/23/25 9:03:44 PM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Golden Arthur F bought $100,000 worth of shares (20,202 units at $4.95), increasing direct ownership by 202% to 30,202 units (SEC Form 4)

    4 - Turn Therapeutics Inc. (0002023016) (Issuer)

    10/23/25 9:01:34 PM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TTRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline

    WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (NASDAQ:TTRX) ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, today announced it has entered into a global supply, development, and license agreement with Medline, the largest provider of medical-surgical products and supply chain solutions serving all points of care. The agreement establishes a long-term collaboration to develop, manufacture, and commercialize products leveraging Turn's proprietary PermaFusion® delivery platform. Turn Therapeutics CEO Bradley Burnam commented, "Partnering with Medline represents a tr

    10/30/25 7:30:00 AM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones

    WESTLAKE VILLAGE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (NASDAQ:TTRX) ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, provides a shareholder update outlining continued progress in the advancement of its clinical programs while highlighting the flexibility of its financing strategy following its dilution-sparing direct listing. Capital Strategy and AlignmentTurn chose a direct listing structure to prioritize flexibility and long-term shareholder alignment. By bypassing traditional crossover rounds and IPO share issuance, early shareholders maintained their ownership position

    10/22/25 8:00:00 AM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025

    LOS ANGELES, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (NASDAQ:TTRX) today announced the launch of a broad communications initiative, featuring a recurring webinar series for shareholders and a forthcoming Founder Blog authored by patient-turned-founder and CEO, Bradley Burnam. "It is an uncommon step to maintain constant engagement with shareholders, partners, and the broader healthcare community," said Bradley Burnam, Founder and CEO of Turn Therapeutics. "But this company was built by a deeply engaged community, and we intend to continue that conversation as we grow." The Founder Blog will publicly share ongoing company updates, research insights, and perspectives on Turn's

    10/20/25 8:22:40 AM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TTRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Board Observer Chesed Abraham bought $65,716 worth of shares (14,286 units at $4.60) (SEC Form 4)

    4 - Turn Therapeutics Inc. (0002023016) (Issuer)

    10/29/25 8:43:04 PM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Chaudhary Zuraiz bought $24,998 worth of shares (5,050 units at $4.95) (SEC Form 4)

    4 - Turn Therapeutics Inc. (0002023016) (Issuer)

    10/23/25 9:03:44 PM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Golden Arthur F bought $100,000 worth of shares (20,202 units at $4.95), increasing direct ownership by 202% to 30,202 units (SEC Form 4)

    4 - Turn Therapeutics Inc. (0002023016) (Issuer)

    10/23/25 9:01:34 PM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TTRX
    SEC Filings

    View All

    Turn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Turn Therapeutics Inc. (0002023016) (Filer)

    10/30/25 7:44:34 AM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Turn Therapeutics Inc.

    424B5 - Turn Therapeutics Inc. (0002023016) (Filer)

    10/29/25 6:08:04 AM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Turn Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Turn Therapeutics Inc. (0002023016) (Filer)

    10/28/25 4:05:58 PM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TTRX
    Leadership Updates

    Live Leadership Updates

    View All

    Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors

    WESTLAKE VILLAGE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces the appointment of Kent E. Kester, MD, FACP, FIDSA, FASTMH to its Board of Directors. Dr. Kester is a globally recognized infectious disease physician and R&D leader with extensive experience spanning clinical development, translational medicine, vaccine and anti-infective innovation, and public-private collaboration. A retired U.S. Army Colonel, he has held senior leadership roles across industry and academia, including as Commander of the Walter Reed Army Inst

    10/15/25 8:00:00 AM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Turn Therapeutics Appoints Arthur Golden to Board of Directors

    WESTLAKE VILLAGE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces the appointment of Arthur Golden, a senior corporate board advisor with extensive experience in M&A transactions, shareholder relations, compliance, and governance, to its Board of Directors. He has decades of experience as a corporate director, most recently as a Director of Emerson Electric where he served for 24 years and chaired the Corporate Governance and Finance Committees and was a member of the Executive Committee. Mr. Golden brings decades of experienc

    10/14/25 12:07:51 PM ET
    $TTRX
    Biotechnology: Pharmaceutical Preparations
    Health Care